Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2020 Financial Results
November 10, 2020 16:01 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Announces Presentation of Body Composition Results from DESTINY PWS, a Phase III Trial of DCCR in Prader-Willi Syndrome
November 03, 2020 16:01 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Announces Late-Breaking Oral Presentation with Body Composition Results from Phase III DESTINY PWS Trial of DCCR in Prader-Willi Syndrome at ObesityWeek® 2020 Meeting
October 29, 2020 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Announces Updated Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome
September 30, 2020 14:40 ET
|
Soleno Therapeutics
Updated Results Demonstrate Significant DCCR Exposure Response Relationship Interim Analysis of Open-Label Extension Data Demonstrate Continued Efficacy Improvements in Body Composition and...
Soleno Therapeutics to Participate in Fireside Chat at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 15, 2020 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...